+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Veterinary Oncology Market By Animal Type, By Therapy, By Cancer Type, By Region, Industry Analysis and Forecast, 2020 - 2026

  • ID: 5026277
  • Report
  • April 2020
  • Region: Global
  • 209 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
1 of 4

FEATURED COMPANIES

  • AB Science SA
  • Regeneus Ltd.
  • Zoetis, Inc.
  • MORE
The Global Veterinary oncology Market size is expected to reach $369.2 Million by 2026, rising at a market growth of 13.2% CAGR during the forecast period. Cancer is one of the main causes of morbidity in veterinary patients and one of the most important surgical procedures undertaken by veterinarians is the surgical removal of tumors. The annual physical examination plays a crucial role in the diagnosis of neoplasia, either specifically through palpation or through paraneoplastic syndromes that can be detected on regular blood and urine analysis. The physical examination allows for the diagnosis of the involvement of cancers and the identification of concurrent conditions that can affect the treatment plan.

When a tumor is identified, the vet records its size, location, and gross appearance, and palpate regional lymph nodes. The suspicion of a metastatic neoplasm rises as the lymph nodes are swollen, solid, or immovable; however, normal lymph node palpation does not guarantee a lack of metastasis. Hence in most cases, some form of biopsy of the lymph node is recommended.

Intralesional, or debulking, surgery is incomplete resection of a tumor (within the pseudo capsule) with the residual gross disease. It is rarely an appropriate cure for neoplastic diseases, be it benign or malignant. This procedure leaves a tumor cell strain that is often too large, even with adjunctive therapies, such as radiation therapy and chemotherapy, to achieve a successful outcome.

Cancer is prevalent in dogs and in recent years, chemotherapy has progressed dramatically with canine oncology becoming a practice in many countries like the UK, Australia, and the US. However, there were no large-scale trials of the potential side effects of chemotherapeutic drugs in associated animals and very little debate on the ethics of using chemotherapy in these species. In general, the prognosis for animals suffering from malignant neoplasia (which can be conducive to chemotherapy) remains low, and the role of oncology in veterinary medicine can be debated.

Based on Animal Type, the market is segmented into Canine and Feline. Based on Therapy, the market is segmented into Chemotherapy, Radiology, Surgery, Immunotherapy and Others. Based on Cancer Type, the market is segmented into Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer and Others. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd.

Strategies deployed in Veterinary Oncology Market

Nov-2019: Varian Medical Systems came into partnership with VCA Animal Hospitals. The partnership was announced as a part of the company's newly launched network of VCA Pet CancerCare Centers across North America for providing advanced pet cancer radiotherapy treatment at its specialty hospitals.

Aug-2019: Elanco Animal Health Inc. signed an agreement to acquire Bayer AG’s animal-health unit. The acquisition is expected to strengthen Elanco's Animal Health business.

Aug-2019: Boehringer Ingelheim signed partnership agreement with The University of Texas MD Anderson Cancer Center. The partnership was focused on conducting collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers.

Jul-2019: Boehringer Ingelheim took over AMAL Therapeutics, a biotechnology company focused on cancer immunotherapy. The acquisition helped the company to become an innovator of novel cancer therapies, including immuno-oncology treatments.

Jul-2019: Elanco Animal Health completed the acquisition of Aratana Therapeutics. The acquisition complemented Elanco’s field presence and capitalized on new opportunities for Elanco pet therapy brands.

Jun-2019: Varian acquired Endocare and Alicon. The acquisition broadened its portfolio of multidisciplinary integrated cancer care solutions.

Jun-2018: Zoetis teamed up with Regeneron Pharmaceuticals. Through this collaboration, the companies aimed to research the use of Regeneron’s monoclonal antibody therapeutics in animals and discover new veterinary treatments.

Jul-2017: PetCure Oncology collaborated with Varian Medical Systems. The collaboration was aimed at bringing a different level of care to pets suffering from cancer. Under this collaboration, the Varian's software suite, including the RapidPlan and ARIA platforms were integrated across PetCure Oncology's national network of veterinary cancer care centers.

May-2017: Karyopharm Therapeutics signed a licensing agreement with Anivive Lifesciences, a biotech company focused on innovations in the veterinary drug and bioinformatics space. Following this agreement, the latter company got the exclusive rights from Karyopharm to research, develop, and commercialize verdinexor (KPT-335) for the treatment of cancer in companion animals.

May-2017: Varian Medical Systems launched the Halcyon system, a new device for cancer treatment. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT). This new treatment system has been designed for expanding the availability of high-quality cancer care and help save the lives of millions more cancer patients

Scope of the Study

Market Segmentation:

By Animal Type
  • Canine and
  • Feline
By Therapy
  • Chemotherapy
  • Radiology
  • Surgery
  • Immunotherapy and
  • Others
By Cancer Type
  • Lymphoma
  • Mast Cell Cancer
  • Mammary & Squamous Cell Cancer and
  • Others
By Geography

North America
  • US
  • Canada
  • Mexico
  • Rest of North America
Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled:
  • Boehringer Ingelheim International GmbH
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • Elanco Animal Health, Inc.
  • Zoetis, Inc.
  • Varian Medical Systems, Inc.
  • PetCure Oncology, LLC (Accelitech, LLC)
  • AB Science SA
  • Rhizen Pharmaceuticals S.A.
  • Nippon Zenyaku Kogyo Co., Ltd.
Unique Offerings from the Publisher:
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AB Science SA
  • Regeneus Ltd.
  • Zoetis, Inc.
  • MORE
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Veterinary Oncology Market, by Animal Type
1.4.2 Global Veterinary Oncology Market, by Therapy
1.4.3 Global Veterinary Oncology Market, by Cancer Type
1.4.4 Global Veterinary Oncology Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Mergers & Acquisitions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2015-2019)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2016, Sep - 2019, Nov) Leading Players

Chapter 4. Global Veterinary Oncology Market by Animal Type
4.1 Global Canine Market by Region
4.2 Global Feline Market by Region

Chapter 5. Global Veterinary Oncology Market by Therapy
5.1 Global Chemotherapy Market by Region
5.2 Global Radiology Market by Region
5.3 Global Surgery Market by Region
5.4 Global Immunotherapy Market by Region
5.5 Global Other Therapy Market by Region

Chapter 6. Global Veterinary Oncology Market by Cancer Type
6.1 Global Lymphoma Market by Region
6.2 Global Mast Cell Cancer Market by Region
6.3 Global Mammary & Squamous Cell Cancer Market by Region
6.4 Global Others Market by Region

Chapter 7. Global Veterinary Oncology Market by Region
7.1 North America Veterinary Oncology Market
7.1.1 North America Veterinary Oncology Market by Animal Type
7.1.1.1 North America Canine Market by Country
7.1.1.2 North America Feline Market by Country
7.1.2 North America Veterinary Oncology Market by Therapy
7.1.2.1 North America Chemotherapy Market by Country
7.1.2.2 North America Radiology Market by Country
7.1.2.3 North America Surgery Market by Country
7.1.2.4 North America Immunotherapy Market by Country
7.1.2.5 North America Other Therapy Market by Country
7.1.3 North America Veterinary Oncology Market by Cancer Type
7.1.3.1 North America Lymphoma Market by Country
7.1.3.2 North America Mast Cell Cancer Market by Country
7.1.3.3 North America Mammary & Squamous Cell Cancer Market by Country
7.1.3.4 North America Others Market by Country
7.1.4 North America Veterinary Oncology Market by Country
7.1.4.1 US Veterinary Oncology Market
7.1.4.1.1 US Veterinary Oncology Market by Animal Type
7.1.4.1.2 US Veterinary Oncology Market by Therapy
7.1.4.1.3 US Veterinary Oncology Market by Cancer Type
7.1.4.2 Canada Veterinary Oncology Market
7.1.4.2.1 Canada Veterinary Oncology Market by Animal Type
7.1.4.2.2 Canada Veterinary Oncology Market by Therapy
7.1.4.2.3 Canada Veterinary Oncology Market by Cancer Type
7.1.4.3 Mexico Veterinary Oncology Market
7.1.4.3.1 Mexico Veterinary Oncology Market by Animal Type
7.1.4.3.2 Mexico Veterinary Oncology Market by Therapy
7.1.4.3.3 Mexico Veterinary Oncology Market by Cancer Type
7.1.4.4 Rest of North America Veterinary Oncology Market
7.1.4.4.1 Rest of North America Veterinary Oncology Market by Animal Type
7.1.4.4.2 Rest of North America Veterinary Oncology Market by Therapy
7.1.4.4.3 Rest of North America Veterinary Oncology Market by Cancer Type
7.2 Europe Veterinary Oncology Market
7.2.1 Europe Veterinary Oncology Market by Animal Type
7.2.1.1 Europe Canine Market by Country
7.2.1.2 Europe Feline Market by Country
7.2.2 Europe Veterinary Oncology Market by Therapy
7.2.2.1 Europe Chemotherapy Market by Country
7.2.2.2 Europe Radiology Market by Country
7.2.2.3 Europe Surgery Market by Country
7.2.2.4 Europe Immunotherapy Market by Country
7.2.2.5 Europe Other Therapy Market by Country
7.2.3 Europe Veterinary Oncology Market by Cancer Type
7.2.3.1 Europe Lymphoma Market by Country
7.2.3.2 Europe Mast Cell Cancer Market by Country
7.2.3.3 Europe Mammary & Squamous Cell Cancer Market by Country
7.2.3.4 Europe Others Market by Country
7.2.4 Europe Veterinary Oncology Market by Country
7.2.4.1 Germany Veterinary Oncology Market
7.2.4.1.1 Germany Veterinary Oncology Market by Animal Type
7.2.4.1.2 Germany Veterinary Oncology Market by Therapy
7.2.4.1.3 Germany Veterinary Oncology Market by Cancer Type
7.2.4.2 UK Veterinary Oncology Market
7.2.4.2.1 UK Veterinary Oncology Market by Animal Type
7.2.4.2.2 UK Veterinary Oncology Market by Therapy
7.2.4.2.3 UK Veterinary Oncology Market by Cancer Type
7.2.4.3 France Veterinary Oncology Market
7.2.4.3.1 France Veterinary Oncology Market by Animal Type
7.2.4.3.2 France Veterinary Oncology Market by Therapy
7.2.4.3.3 France Veterinary Oncology Market by Cancer Type
7.2.4.4 Russia Veterinary Oncology Market
7.2.4.4.1 Russia Veterinary Oncology Market by Animal Type
7.2.4.4.2 Russia Veterinary Oncology Market by Therapy
7.2.4.4.3 Russia Veterinary Oncology Market by Cancer Type
7.2.4.5 Spain Veterinary Oncology Market
7.2.4.5.1 Spain Veterinary Oncology Market by Animal Type
7.2.4.5.2 Spain Veterinary Oncology Market by Therapy
7.2.4.5.3 Spain Veterinary Oncology Market by Cancer Type
7.2.4.6 Italy Veterinary Oncology Market
7.2.4.6.1 Italy Veterinary Oncology Market by Animal Type
7.2.4.6.2 Italy Veterinary Oncology Market by Therapy
7.2.4.6.3 Italy Veterinary Oncology Market by Cancer Type
7.2.4.7 Rest of Europe Veterinary Oncology Market
7.2.4.7.1 Rest of Europe Veterinary Oncology Market by Animal Type
7.2.4.7.2 Rest of Europe Veterinary Oncology Market by Therapy
7.2.4.7.3 Rest of Europe Veterinary Oncology Market by Cancer Type
7.3 Asia Pacific Veterinary Oncology Market
7.3.1 Asia Pacific Veterinary Oncology Market by Animal Type
7.3.1.1 Asia Pacific Canine Market by Country
7.3.1.2 Asia Pacific Feline Market by Country
7.3.2 Asia Pacific Veterinary Oncology Market by Therapy
7.3.2.1 Asia Pacific Chemotherapy Market by Country
7.3.2.2 Asia Pacific Radiology Market by Country
7.3.2.3 Asia Pacific Surgery Market by Country
7.3.2.4 Asia Pacific Immunotherapy Market by Country
7.3.2.5 Asia Pacific Other Therapy Market by Country
7.3.3 Asia Pacific Veterinary Oncology Market by Cancer Type
7.3.3.1 Asia Pacific Lymphoma Market by Country
7.3.3.2 Asia Pacific Mast Cell Cancer Market by Country
7.3.3.3 Asia Pacific Mammary & Squamous Cell Cancer Market by Country
7.3.3.4 Asia Pacific Others Market by Country
7.3.4 Asia Pacific Veterinary Oncology Market by Country
7.3.4.1 China Veterinary Oncology Market
7.3.4.1.1 China Veterinary Oncology Market by Animal Type
7.3.4.1.2 China Veterinary Oncology Market by Therapy
7.3.4.1.3 China Veterinary Oncology Market by Cancer Type
7.3.4.2 Japan Veterinary Oncology Market
7.3.4.2.1 Japan Veterinary Oncology Market by Animal Type
7.3.4.2.2 Japan Veterinary Oncology Market by Therapy
7.3.4.2.3 Japan Veterinary Oncology Market by Cancer Type
7.3.4.3 India Veterinary Oncology Market
7.3.4.3.1 India Veterinary Oncology Market by Animal Type
7.3.4.3.2 India Veterinary Oncology Market by Therapy
7.3.4.3.3 India Veterinary Oncology Market by Cancer Type
7.3.4.4 South Korea Veterinary Oncology Market
7.3.4.4.1 South Korea Veterinary Oncology Market by Animal Type
7.3.4.4.2 South Korea Veterinary Oncology Market by Therapy
7.3.4.4.3 South Korea Veterinary Oncology Market by Cancer Type
7.3.4.5 Singapore Veterinary Oncology Market
7.3.4.5.1 Singapore Veterinary Oncology Market by Animal Type
7.3.4.5.2 Singapore Veterinary Oncology Market by Therapy
7.3.4.5.3 Singapore Veterinary Oncology Market by Cancer Type
7.3.4.6 Malaysia Veterinary Oncology Market
7.3.4.6.1 Malaysia Veterinary Oncology Market by Animal Type
7.3.4.6.2 Malaysia Veterinary Oncology Market by Therapy
7.3.4.6.3 Malaysia Veterinary Oncology Market by Cancer Type
7.3.4.7 Rest of Asia Pacific Veterinary Oncology Market
7.3.4.7.1 Rest of Asia Pacific Veterinary Oncology Market by Animal Type
7.3.4.7.2 Rest of Asia Pacific Veterinary Oncology Market by Therapy
7.3.4.7.3 Rest of Asia Pacific Veterinary Oncology Market by Cancer Type
7.4 LAMEA Veterinary Oncology Market
7.4.1 LAMEA Veterinary Oncology Market by Animal Type
7.4.1.1 LAMEA Canine Market by Country
7.4.1.2 LAMEA Feline Market by Country
7.4.2 LAMEA Veterinary Oncology Market by Therapy
7.4.2.1 LAMEA Chemotherapy Market by Country
7.4.2.2 LAMEA Radiology Market by Country
7.4.2.3 LAMEA Surgery Market by Country
7.4.2.4 LAMEA Immunotherapy Market by Country
7.4.2.5 LAMEA Other Therapy Market by Country
7.4.3 LAMEA Veterinary Oncology Market by Cancer Type
7.4.3.1 LAMEA Lymphoma Market by Country
7.4.3.2 LAMEA Mast Cell Cancer Market by Country
7.4.3.3 LAMEA Mammary & Squamous Cell Cancer Market by Country
7.4.3.4 LAMEA Others Market by Country
7.4.4 LAMEA Veterinary Oncology Market by Country
7.4.4.1 Brazil Veterinary Oncology Market
7.4.4.1.1 Brazil Veterinary Oncology Market by Animal Type
7.4.4.1.2 Brazil Veterinary Oncology Market by Therapy
7.4.4.1.3 Brazil Veterinary Oncology Market by Cancer Type
7.4.4.2 Argentina Veterinary Oncology Market
7.4.4.2.1 Argentina Veterinary Oncology Market by Animal Type
7.4.4.2.2 Argentina Veterinary Oncology Market by Therapy
7.4.4.2.3 Argentina Veterinary Oncology Market by Cancer Type
7.4.4.3 UAE Veterinary Oncology Market
7.4.4.3.1 UAE Veterinary Oncology Market by Animal Type
7.4.4.3.2 UAE Veterinary Oncology Market by Therapy
7.4.4.3.3 UAE Veterinary Oncology Market by Cancer Type
7.4.4.4 Saudi Arabia Veterinary Oncology Market
7.4.4.4.1 Saudi Arabia Veterinary Oncology Market by Animal Type
7.4.4.4.2 Saudi Arabia Veterinary Oncology Market by Therapy
7.4.4.4.3 Saudi Arabia Veterinary Oncology Market by Cancer Type
7.4.4.5 South Africa Veterinary Oncology Market
7.4.4.5.1 South Africa Veterinary Oncology Market by Animal Type
7.4.4.5.2 South Africa Veterinary Oncology Market by Therapy
7.4.4.5.3 South Africa Veterinary Oncology Market by Cancer Type
7.4.4.6 Nigeria Veterinary Oncology Market
7.4.4.6.1 Nigeria Veterinary Oncology Market by Animal Type
7.4.4.6.2 Nigeria Veterinary Oncology Market by Therapy
7.4.4.6.3 Nigeria Veterinary Oncology Market by Cancer Type
7.4.4.7 Rest of LAMEA Veterinary Oncology Market
7.4.4.7.1 Rest of LAMEA Veterinary Oncology Market by Animal Type
7.4.4.7.2 Rest of LAMEA Veterinary Oncology Market by Therapy
7.4.4.7.3 Rest of LAMEA Veterinary Oncology Market by Cancer Type

Chapter 8. Company Profiles
8.1 Boehringer Ingelheim International GmbH
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Karyopharm Therapeutics, Inc.
8.2.1 Company overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Regeneus Ltd.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expense
8.4 Elanco Animal Health, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.5 Zoetis, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Varian Medical Systems, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.6.5.2 Partnerships, Collaborations, and Agreements:
8.6.5.3 Product Launches and Product Expansions:
8.7 PetCure Oncology, LLC (Accelitech, LLC)
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Partnerships, Collaborations, and Agreements:
8.8 AB Science SA
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Research & Development Expense
8.9 Rhizen Pharmaceuticals S.A.
8.9.1 Company Overview
8.1 Nippon Zenyaku Kogyo Co., Ltd.
8.10.1 Company Overview
Note: Product cover images may vary from those shown
3 of 4
  • Boehringer Ingelheim International GmbH
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • Elanco Animal Health, Inc.
  • Zoetis, Inc.
  • Varian Medical Systems, Inc.
  • PetCure Oncology, LLC (Accelitech, LLC)
  • AB Science SA
  • Rhizen Pharmaceuticals S.A.
  • Nippon Zenyaku Kogyo Co., Ltd.
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll